Barclays PLC Buys Shares of 19,616 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Barclays PLC bought a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 19,616 shares of the company’s stock, valued at approximately $304,000. Barclays PLC owned 0.08% of Artiva Biotherapeutics at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at $623,000. BNP Paribas Financial Markets purchased a new position in Artiva Biotherapeutics during the 3rd quarter valued at about $42,000. MetLife Investment Management LLC acquired a new position in Artiva Biotherapeutics in the 3rd quarter valued at about $135,000. Acuta Capital Partners LLC purchased a new stake in Artiva Biotherapeutics during the third quarter worth about $680,000. Finally, RTW Investments LP acquired a new stake in shares of Artiva Biotherapeutics during the third quarter worth about $2,300,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. HC Wainwright assumed coverage on shares of Artiva Biotherapeutics in a research note on Monday, December 30th. They issued a “buy” rating and a $20.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $21.00.

Artiva Biotherapeutics Stock Down 3.7 %

NASDAQ:ARTV opened at $6.53 on Tuesday. Artiva Biotherapeutics, Inc. has a 1 year low of $6.50 and a 1 year high of $17.31. The business’s 50-day simple moving average is $10.61.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). As a group, research analysts forecast that Artiva Biotherapeutics, Inc. will post -4.95 earnings per share for the current year.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.